Top 5 Most Read RNS's on Vox Markets for Wednesday 5th October 2022
Episode 938, Oct 05, 2022, 06:49 AM
5. i3 Energy PLC #I3E - November 2022 Dividend Declaration
i3 announces its monthly dividend totalling £1.6996 million and confirms the following: Dividend: 0.1425 pence/share & Ex-Dividend Date: 13 Oct 2022
4. Serinus Energy PLC #SENX - Moftinu Nord-1 Well and Tunisia Update
The Moftinu Nord-1 well which was targeting four prospective hydrocarbon zones do not contain sufficient gas resources to justify proceeding with the testing and completion program for the well.
3. Genedrive PLC #GDR - US FDA pre-submission for Genedrive MT-RNR1 kit
It has commenced engagement with the U.S. Food and Drug Administration to progress the regulatory approval of the Genedrive® MT-RNR1 ID Kit into the USA.
2. Horizonte Minerals #HZM - Results of oversubscribed Fundraise
Following significant institutional demand in the bookbuild from existing and new investors, the Board decided to upsize the Placing, increasing the gross proceeds from approximately £61.7 million to £70.5 million at a price of 90.5 pence per Placing Share.
1. Omega Diagnostics Gp #ODX - Positive WHO data received for VISITECT® CD4 test
Test shows high diagnostic accuracy (specificity and sensitivity).
i3 announces its monthly dividend totalling £1.6996 million and confirms the following: Dividend: 0.1425 pence/share & Ex-Dividend Date: 13 Oct 2022
4. Serinus Energy PLC #SENX - Moftinu Nord-1 Well and Tunisia Update
The Moftinu Nord-1 well which was targeting four prospective hydrocarbon zones do not contain sufficient gas resources to justify proceeding with the testing and completion program for the well.
3. Genedrive PLC #GDR - US FDA pre-submission for Genedrive MT-RNR1 kit
It has commenced engagement with the U.S. Food and Drug Administration to progress the regulatory approval of the Genedrive® MT-RNR1 ID Kit into the USA.
2. Horizonte Minerals #HZM - Results of oversubscribed Fundraise
Following significant institutional demand in the bookbuild from existing and new investors, the Board decided to upsize the Placing, increasing the gross proceeds from approximately £61.7 million to £70.5 million at a price of 90.5 pence per Placing Share.
1. Omega Diagnostics Gp #ODX - Positive WHO data received for VISITECT® CD4 test
Test shows high diagnostic accuracy (specificity and sensitivity).